Brickell is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases.
Our current pipeline consists of new molecular entities with relevant mechanisms of action in skin diseases, targeting significant market opportunities in the global dermatology market.
Our current pipeline consists of new molecular entities targeting the treatment of the following indications:
- Cutaneous T-cell Lymphoma
- Allergic Contact Dermatitis
- Androgenic Alopecia
Brickell Biotech Appoints Top Lilly Executive, Robert Brown, As Chief Executive Officer
Notable leadership change comes as Brickell prepares to progress its lead product candidate, sofpironium bromide, to Phase 3 clinical trials in primary axillary hyperhidrosis (excessive underarm sweating) BOULDER, CO, November…
Phase 2b Study Results Presented at the 76th American Academy of Dermatology Annual Meeting at the Late-Breaking Research Forum
SAN DIEGO, CA, February 20, 2018 – Brickell Biotech, Inc. (Brickell), a clinical-stage medical dermatology company, today announced that the positive confirmatory Phase 2b study (CL-203) results with sofpironium bromide…